



Reblozyl® (luspaterecept-aamt) Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: **1-866-752-7021** (TTY: **711**)
FAX: **1-888-267-3277**

For Medicare Advantage Part B:
Please Use Medicare Request Form

Please indicate: Start of treatment: Start date ____ / ____ / ____
 Continuation of therapy: Date of last treatment ____ / ____ / ____

Precertification Requested By: _____ **Phone:** _____ **Fax:** _____

A. PATIENT INFORMATION

First Name:		Last Name:		
Address:		City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:		
DOB:	Allergies:	Email:		
Current Weight: _____ lbs or _____ kgs		Height: _____ inches or _____ cms		

B. INSURANCE INFORMATION

Aetna Member ID #: _____	Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No
Group #: _____	If yes, provide ID#: _____ Carrier Name: _____
Insured: _____	Insured: _____
Medicare: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____	Medicaid: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____

C. PRESCRIBER INFORMATION

First Name:		Last Name:		(Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.		
Address:		City:	State:	ZIP:		
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:	
Provider Email:		Office Contact Name:			Phone:	
Specialty (Check one): <input type="checkbox"/> Oncologist <input type="checkbox"/> Other: _____						

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration: <input type="checkbox"/> Self-administered <input type="checkbox"/> Physician's Office <input type="checkbox"/> Outpatient Infusion Center Phone: _____ Center Name: _____ <input type="checkbox"/> Home Infusion Center Phone: _____ Agency Name: _____ <input type="checkbox"/> Administration code(s) (CPT): _____ Address: _____	Dispensing Provider/Pharmacy: Patient Selected choice <input type="checkbox"/> Physician's Office <input type="checkbox"/> Retail Pharmacy <input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Other: _____ Name: _____ Address: _____ Phone: _____ Fax: _____ TIN: _____ PIN: _____
---	--

E. PRODUCT INFORMATION

Request is for Reblozyl (luspaterecept-aamt) Dose: _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____ **Secondary ICD Code:** _____ **Other ICD Code:** _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

For Initiation Requests (clinical documentation required for all requests):

Anemia with beta thalassemia:

Yes No Does the patient have a diagnosis of hemoglobin S/β-thalassemia or alpha thalassemia?

Yes No Has the diagnosis of beta thalassemia or hemoglobin E/beta-thalassemia been confirmed by hemoglobin electrophoresis, high-performance liquid chromatography (HPLC) or molecular genetic testing?

Yes No Are there chart notes or medical record documentation stating the patient's diagnosis of beta thalassemia or hemoglobin E/beta-thalassemia was previously confirmed by appropriate testing (e.g., hemoglobin electrophoresis or high-performance liquid chromatography [HPLC], molecular genetic testing)?

Yes No Prior to starting treatment with the requested drug, does the patient have symptomatic anemia?

Yes No Has the patient's pretreatment or pretransfusion hemoglobin (Hgb) level been drawn?

Yes No Please indicate the hemoglobin level: _____ grams per deciliter

Yes No Did the patient require at least 6 red blood cell units to be transfused in the previous 24 weeks?

Anemia associated with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm or Anemia associated with hemoglobin E/beta-thalassemia

Yes No Does the patient have one of the following: A) very low to intermediate risk myelodysplastic syndrome or B) myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)?

Yes No Prior to starting treatment with the requested drug, does the patient have symptomatic anemia?

Continued on next page



Reblozyl® (luspatercept-aamt)
Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 (TTY: 711)
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.

Yes No Has the patient's pretreatment or pretransfusion hemoglobin (Hgb) level been drawn?
 _____ → Please indicate the hemoglobin level: _____ grams per deciliter

Yes No Has the patient been receiving regular red blood cell transfusions as defined by greater than or equal to 2 units per 8 weeks?

For Continuation Requests (clinical documentation required for all requests):

Yes No Has the patient achieved or maintained a reduction in red blood cell transfusion burden?

Yes No Has the patient experienced an unacceptable toxicity while taking the requested medication?

H. ACKNOWLEDGEMENT

Request Completed By (Signature Required): _____ **Date:** ____ / ____ / ____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.